Attention-Deficit–Hyperactivity Disorder

To the Editor: In their review of attention-deficit–hyperactivity disorder (ADHD), Zametkin and Ernst (Jan. 7 issue) 1 acknowledged the eightfold rise in the use of stimulants in the United States over the past decade. They did not mention that the use of methylphenidate (Ritalin) in the United Stat...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 340; no. 22; pp. 1766 - 1767
Main Author Diller, L H
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 03.06.1999
Subjects
Attention Deficit Disorder with Hyperactivity - drug therapy
Central Nervous System Stimulants - therapeutic use
Cultural Characteristics
Drug Utilization - statistics & numerical data
Humans
Methylphenidate - therapeutic use
United States
United States
Online AccessGet full text

Cover

More Information
Summary:To the Editor: In their review of attention-deficit–hyperactivity disorder (ADHD), Zametkin and Ernst (Jan. 7 issue) 1 acknowledged the eightfold rise in the use of stimulants in the United States over the past decade. They did not mention that the use of methylphenidate (Ritalin) in the United States accounts for 90 percent of the use worldwide. 2 In the United States, per capita use of methylphenidate varies sixfold among states. 3 Within individual states, analyses based on ZIP Codes show 20-fold variations from one community to the next. 3 Such large variations in the use of stimulants point to factors other than neurologic ones . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJM199906033402216